Clinical Trials Browser

Interventional × TH 302 × Gastrointestinal × Clear all

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02047500 2025-05-11

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase 1 Terminated

19 enrolled 6 charts

Gastrointestinal

Pancreatic Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Phase 1/2 Recruiting

71 enrolled

GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Phase 2 Completed

17 enrolled 55 charts

EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01497444 2020-02-06

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Phase 1 Completed

24 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms

NCT01833546 2018-10-15

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Phase 1 Completed

20 enrolled 35 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase 1 Unknown

69 enrolled

DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02598687 2016-04-21

Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Phase 1 Withdrawn

Gastrointestinal

Esophageal Neoplasms

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Phase 1/2 Completed

71 enrolled

GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01381822 2014-04-21

TH-CR-410

Phase 1 Unknown

58 enrolled

GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

Clinical Trials

MAESTRO

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

TH-CR-410